FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2610394265> ?p ?o ?g. }

• W2610394265 abstract "Transradial approach has significantly decreased the rate of access site bleeding in patients undergoing percutaneous coronary interventions (PCI), therefore potentially mitigating the benefits offered by bivalirudin in lowering major bleeding complications as compared to heparin. However, nonaccess site bleeding, that represent the majority of hemorrhagic complications, still carry negative prognostic consequences for these patients and no study has so far defined the exact impact of bivalirudin on nonaccess site bleeding, that was therefore the aim of present meta-analysis.Literature archives (Pubmed, EMBASE, Cochrane) and main scientific sessions were scanned comparing bivalirudin vs. heparin in patients undergoing PCI. Primary endpoint was the occurrence of nonaccess site bleeding within 30 days. Secondary endpoints were 30 days mortality and the occurrence of access-site bleeding.A total of nine randomized clinical trials were finally included, involving 32,587 patients, 55.8% randomized to bivalirudin. Bivalirudin significantly reduced the rate of nonaccess site bleeding (2.6 vs. 3.8%, OR [95% CI] = 0.68 [0.60-0.77], P < 0.00001, Phet = 0.10). However, the reduction of hemorrhagic events was more pronounced when bivalirudin was compared to heparin plus glycoprotein IIbIIIa inhibitors than when it was compared to heparin alone (r = -0.01 (-0.02; -0.001), P = 0.02). Similar results were observed for access-site bleeding (OR [95% CI] = 0.67 [0.57-0.79], P < 0.000001, Phet = 0.10), with a significant role of glycoprotein IIbIIIa inhibitors use (r = -0.02 (-0.04; -0.004), P = 0.017). Moreover, the observed benefits in hemorrhagic complications did not translate into mortality benefits (OR [95% CI] = 0.89 [0.76-1.05], P = 0.18; Phet = 0.12; r = 0.21 (-1.12; 1.53), P = 0.76).The present meta-analysis shows that bivalirudin can provide a significant reduction of both access and nonaccess site bleeding in patients undergoing PCI. However, these hemorrhagic benefits did not impact on survival, and moreover, were significantly conditioned by the association of heparin with potent antithrombotic strategies, such as glycoprotein IIbIIIa inhibitors, rather than by heparin or bivalirudin alone. Therefore, we could not provide any clinical evidence for the routine use of bivalirudin as preferred anticoagulation strategy for PCI. © 2017 Wiley Periodicals, Inc." @default.
• W2610394265 created "2017-05-12" @default.
• W2610394265 creator A5000400608 @default.
• W2610394265 creator A5015479782 @default.
• W2610394265 creator A5024732332 @default.
• W2610394265 creator A5064670948 @default.
• W2610394265 creator A5068649190 @default.
• W2610394265 creator A5077517566 @default.
• W2610394265 creator A5085268431 @default.
• W2610394265 date "2017-05-04" @default.
• W2610394265 modified "2023-09-27" @default.
• W2610394265 title "Impact of anticoagulation strategy with bivalirudin or heparin on nonaccess site bleeding in percutaneous coronary interventions: A meta-analysis of randomized trials" @default.
• W2610394265 cites W1278248171 @default.
• W2610394265 cites W1473004 @default.
• W2610394265 cites W1806482666 @default.
• W2610394265 cites W1957635101 @default.
• W2610394265 cites W1971157734 @default.
• W2610394265 cites W1988996988 @default.
• W2610394265 cites W2004110783 @default.
• W2610394265 cites W2012932483 @default.
• W2610394265 cites W2016463307 @default.
• W2610394265 cites W2019002307 @default.
• W2610394265 cites W2024431383 @default.
• W2610394265 cites W2024692328 @default.
• W2610394265 cites W2034358332 @default.
• W2610394265 cites W2070261961 @default.
• W2610394265 cites W2073537981 @default.
• W2610394265 cites W2082333685 @default.
• W2610394265 cites W2103428481 @default.
• W2610394265 cites W2105397247 @default.
• W2610394265 cites W2105626305 @default.
• W2610394265 cites W2112255365 @default.
• W2610394265 cites W2114758846 @default.
• W2610394265 cites W2119311183 @default.
• W2610394265 cites W2130652855 @default.
• W2610394265 cites W2142825093 @default.
• W2610394265 cites W2143763771 @default.
• W2610394265 cites W2149933092 @default.
• W2610394265 doi "https://doi.org/10.1002/ccd.26967" @default.
• W2610394265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28471057" @default.
• W2610394265 hasPublicationYear "2017" @default.
• W2610394265 type Work @default.
• W2610394265 sameAs 2610394265 @default.
• W2610394265 citedByCount "0" @default.
• W2610394265 crossrefType "journal-article" @default.
• W2610394265 hasAuthorship W2610394265A5000400608 @default.
• W2610394265 hasAuthorship W2610394265A5015479782 @default.
• W2610394265 hasAuthorship W2610394265A5024732332 @default.
• W2610394265 hasAuthorship W2610394265A5064670948 @default.
• W2610394265 hasAuthorship W2610394265A5068649190 @default.
• W2610394265 hasAuthorship W2610394265A5077517566 @default.
• W2610394265 hasAuthorship W2610394265A5085268431 @default.
• W2610394265 hasConcept C126322002 @default.
• W2610394265 hasConcept C141071460 @default.
• W2610394265 hasConcept C164705383 @default.
• W2610394265 hasConcept C168563851 @default.
• W2610394265 hasConcept C187960798 @default.
• W2610394265 hasConcept C203092338 @default.
• W2610394265 hasConcept C2777557582 @default.
• W2610394265 hasConcept C2777565915 @default.
• W2610394265 hasConcept C2780400711 @default.
• W2610394265 hasConcept C2780813298 @default.
• W2610394265 hasConcept C45393284 @default.
• W2610394265 hasConcept C500558357 @default.
• W2610394265 hasConcept C71924100 @default.
• W2610394265 hasConcept C95190672 @default.
• W2610394265 hasConceptScore W2610394265C126322002 @default.
• W2610394265 hasConceptScore W2610394265C141071460 @default.
• W2610394265 hasConceptScore W2610394265C164705383 @default.
• W2610394265 hasConceptScore W2610394265C168563851 @default.
• W2610394265 hasConceptScore W2610394265C187960798 @default.
• W2610394265 hasConceptScore W2610394265C203092338 @default.
• W2610394265 hasConceptScore W2610394265C2777557582 @default.
• W2610394265 hasConceptScore W2610394265C2777565915 @default.
• W2610394265 hasConceptScore W2610394265C2780400711 @default.
• W2610394265 hasConceptScore W2610394265C2780813298 @default.
• W2610394265 hasConceptScore W2610394265C45393284 @default.
• W2610394265 hasConceptScore W2610394265C500558357 @default.
• W2610394265 hasConceptScore W2610394265C71924100 @default.
• W2610394265 hasConceptScore W2610394265C95190672 @default.
• W2610394265 hasLocation W26103942651 @default.
• W2610394265 hasLocation W26103942652 @default.
• W2610394265 hasOpenAccess W2610394265 @default.
• W2610394265 hasPrimaryLocation W26103942651 @default.
• W2610394265 hasRelatedWork W2085646007 @default.
• W2610394265 hasRelatedWork W2216221729 @default.
• W2610394265 hasRelatedWork W2290039859 @default.
• W2610394265 hasRelatedWork W2541799534 @default.
• W2610394265 hasRelatedWork W2577772076 @default.
• W2610394265 hasRelatedWork W2597286413 @default.
• W2610394265 hasRelatedWork W2612568885 @default.
• W2610394265 hasRelatedWork W2615685689 @default.
• W2610394265 hasRelatedWork W2791849070 @default.
• W2610394265 hasRelatedWork W2792549215 @default.
• W2610394265 isParatext "false" @default.
• W2610394265 isRetracted "false" @default.
• W2610394265 magId "2610394265" @default.
• W2610394265 workType "article" @default.